Immunohistochemical Characterization of Three Monoclonal Antibodies Raised against the Epidermal Growth Factor and Its Receptor in Non-Small-Cell Lung Cancer: Their Potential Use in the Selection of Patients for Immunotherapy

Figure 4

Antiproliferative activity of ior egf/r3 Mab in cultures of NCI-H125 cells. (a) Known numbers of NCI-H125 cells were treated with the indicated concentrations of anti-EGFR Mab and cultured for 72 h. The maximum of cell growth inhibition was obtained at 100 μg/mL. Data points, means of triplicate samples; bars, SE. (b) Cells cultures were incubated for 72 with ior egf/r3 Mab at 100 μg/mL following 3 different treatment designs (Materials and Methods). See: The statistical significant differences between treatment 1 and 3 (S phase, 0.0149; ANOVA). (c) and (d) Representative flow cytometry histograms of the NCI-H125 cells treated with the irrelevant Mab and with ior egf/r3 Mab, respectively. (d) Note an increase in the percentage of cells undergoing apoptosis (area in gray color) as well as the decrease in the percentage of cells in S phase (area in blue color).